103 related articles for article (PubMed ID: 21294474)
21. Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient.
Wilgenhof S; Neyns B
Ann Oncol; 2011 Apr; 22(4):991-993. PubMed ID: 21357649
[No Abstract] [Full Text] [Related]
22. Ipilimumab.
Sondak VK; Smalley KS; Kudchadkar R; Grippon S; Kirkpatrick P
Nat Rev Drug Discov; 2011 Jun; 10(6):411-2. PubMed ID: 21629286
[No Abstract] [Full Text] [Related]
23. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma.
Kähler KC; Hauschild A
J Dtsch Dermatol Ges; 2011 Apr; 9(4):277-86. PubMed ID: 21083648
[TBL] [Abstract][Full Text] [Related]
24. Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications.
Calabrò L; Danielli R; Sigalotti L; Maio M
Semin Oncol; 2010 Oct; 37(5):460-7. PubMed ID: 21074061
[TBL] [Abstract][Full Text] [Related]
25. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.
O'Day SJ; Hamid O; Urba WJ
Cancer; 2007 Dec; 110(12):2614-27. PubMed ID: 18000991
[TBL] [Abstract][Full Text] [Related]
26. Pembrolizumab superior to ipilimumab in melanoma.
Cancer Discov; 2015 Jun; 5(6):568. PubMed ID: 25895921
[TBL] [Abstract][Full Text] [Related]
27. Recent advances using anti-CTLA-4 for the treatment of melanoma.
Sarnaik AA; Weber JS
Cancer J; 2009; 15(3):169-73. PubMed ID: 19556898
[TBL] [Abstract][Full Text] [Related]
28. Current and Emerging Perspectives on Immunotherapy for Melanoma.
Daud A
Semin Oncol; 2015 Dec; 42 Suppl 3():S3-S11. PubMed ID: 26598057
[TBL] [Abstract][Full Text] [Related]
29. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.
Maker AV; Phan GQ; Attia P; Yang JC; Sherry RM; Topalian SL; Kammula US; Royal RE; Haworth LR; Levy C; Kleiner D; Mavroukakis SA; Yellin M; Rosenberg SA
Ann Surg Oncol; 2005 Dec; 12(12):1005-16. PubMed ID: 16283570
[TBL] [Abstract][Full Text] [Related]
30. Industry makes strides in melanoma.
Garber K
Nat Biotechnol; 2010 Aug; 28(8):763-4. PubMed ID: 20697383
[No Abstract] [Full Text] [Related]
31. No correlation between clinical response to CTLA-4 blockade and presence of NY-ESO-1 antibody in patients with metastatic melanoma.
Goff SL; Robbins PF; El-Gamil M; Rosenberg SA
J Immunother; 2009 Oct; 32(8):884-5. PubMed ID: 19752745
[No Abstract] [Full Text] [Related]
32. Anti-CTLA-4 antibody adjuvant therapy in melanoma.
Eggermont AM; Testori A; Maio M; Robert C
Semin Oncol; 2010 Oct; 37(5):455-9. PubMed ID: 21074060
[TBL] [Abstract][Full Text] [Related]
33. Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma.
Gordon IO; Wade T; Chin K; Dickstein J; Gajewski TF
Cancer Immunol Immunother; 2009 Aug; 58(8):1351-3. PubMed ID: 19052742
[No Abstract] [Full Text] [Related]
34. Treating cancer by targeting the immune system.
Hwu P
N Engl J Med; 2010 Aug; 363(8):779-81. PubMed ID: 20818880
[No Abstract] [Full Text] [Related]
35. Ipilimumab.
Drugs R D; 2010; 10(2):97-110. PubMed ID: 20698719
[TBL] [Abstract][Full Text] [Related]
36. T-cell activation and maturation at tumor site associated with objective response to ipilimumab in metastatic melanoma.
Del Vecchio M; Mortarini R; Tragni G; Di Guardo L; Bersani I; Di Tolla G; Agustoni F; Colonna V; Weber JS; Anichini A
J Clin Oncol; 2011 Nov; 29(32):e783-8. PubMed ID: 21990398
[No Abstract] [Full Text] [Related]
37. Introduction. Immune-modulating antibodies.
Weber J
Oncologist; 2008; 13 Suppl 4():1. PubMed ID: 19001144
[No Abstract] [Full Text] [Related]
38. Immunotherapy as an adjuvant therapy in the management of advanced, surgically resected, melanoma.
Kalani AD; Jack A; Montenegro G; Degliuomini J; Wallack MK
G Ital Dermatol Venereol; 2008 Feb; 143(1):59-70. PubMed ID: 18833052
[TBL] [Abstract][Full Text] [Related]
39. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.
Boasberg P; Hamid O; O'Day S
Semin Oncol; 2010 Oct; 37(5):440-9. PubMed ID: 21074058
[TBL] [Abstract][Full Text] [Related]
40. [When CRAF takes over BRAF in melanoma].
Dumaz N; Bagot M; Bensussan A
Med Sci (Paris); 2011 Oct; 27(10):817-9. PubMed ID: 22027417
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]